Pilot Investigation of Stem Cells in Stroke Phase II Efficacy (PISCES-II)
|ClinicalTrials.gov Identifier: NCT02117635|
Recruitment Status : Completed
First Posted : April 21, 2014
Last Update Posted : December 5, 2017
The primary aim of this Phase II trial is to determine whether it is sufficiently likely that CTX DP treatment at a dose level of 20 million cells improves the recovery in the use of the paretic arm in acute stroke patients to justify a subsequent larger prospectively controlled study.
This study will evaluate the safety and efficacy of intracerebral CTX DP at a dose level of 20 million cells in patients with paresis of an arm following an ischaemic middle cerebral artery (MCA) stoke. Eligible patients will have no useful function of the paretic arm a minimum of 28 days after the ischaemic stroke (a modified NIH Stroke Scale (NIHSS) Motor Arm Score of 2, 3 or 4 for the affected arm).
|Condition or disease||Intervention/treatment||Phase|
|Ischaemic Stroke Cerebral Infarction Hemiparesis Arm Paralysis||Biological: CTX DP||Phase 2|
Design: This Phase II efficacy trial is a multi-centre, open label, single arm, non-comparative design, administering a single dose of CTX cells 2 to 3 months post-ischaemic stroke with follow-up over 12 months. The trial will be overseen by an independent DSMB. The DSMB will adjudicate at predetermined intervals whether a patient has satisfied the primary response criterion and whether the ongoing safety profile justifies continuation or modification of the study.
At least 21 patients will be enrolled to receive CTX DP (20 million cells) by stereotaxic intra-striatal injection ipsilateral to the location of the MCA ischaemic stroke.
Pre-treatment selection of patients: Men and women, aged 40 or more, supratentorial ischaemic stroke or a stroke with elements of both in an area perfused by the MCA (i.e. stroke due to ischaemia resulting in infarct located in the basal ganglia, internal capsule, or corona radiata or a stroke due to ischaemia resulting in infarction of part of the cerebral cortex).
Patients with a first stroke within the past 4 weeks (at time of consent) satisfying the following criteria: Modified NIHSS Motor Arm Score of 2 (some effort against gravity), 3 (no movement against gravity) or 4 (no movement) for the paretic arm post ischaemic stroke; Clinical diagnosis of stroke confirmed by physician using neuro-imaging (computerised tomography or magnetic resonance imaging). A Score of 0 or 1 for test 2 of the ARAT at visit 1 and 2 using the affected arm.
Treatment: One patient will be treated at one time. A single dose (20 million) of CTX DP cells will be administered intracranially via stereotaxic neurosurgery.
Post-treatment follow-up: Patients will be followed for 12 months post-implantation.
End-points: The primary endpoint of the trial is efficacy, using ARAT. Secondary endpoints are efficacy and safety. Outcome measures for efficacy include Fugl-Meyer, NIHSS, BI and RFA. Safety will be assessed by incidence of relevant adverse events monitoring patient's general physical condition and clinical measures (temperature, pulse rate and rhythm, ECG, blood pressure, full blood count, liver function tests, serum urea and electrolytes), immunological response and concomitant medications at the 7 follow-up visits to the clinic in the first year after treatment.
Post-trial follow-up: Annual correspondence with family practitioners; Life-long follow-up for new diagnosis of cancer, site of primary tumour, and survival via National Cancer Registry.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Efficacy Study of Intracerebral CTX0E03 DP in Patients With Stable Paresis of the Arm Following an Ischaemic Stroke.|
|Study Start Date :||June 2014|
|Actual Primary Completion Date :||August 16, 2017|
|Actual Study Completion Date :||August 16, 2017|
Experimental: allogeneic human neural stem cell
human neural stem cell product, single dose once only injection
Biological: CTX DP
20 million cell dose administered by surgery to the damaged area of the brain
- Action Research Arm Test (ARAT) [ Time Frame: 3 months ]
The primary outcome measure is a minimum 2 point improvement in the ARAT test number 2 (Yozbatiran et al., 2008).
Response will be defined as a minimum improvement of 2 points in test number 2 of the ARAT (Grasp a 2.5 cm3 block and move it from the starting position to the target end position) in the affected arm 6 months after injection of CTX DP. This would represent an improvement from a pre-treatment state in which the patient was unable to grasp and reposition the block as required to a post-treatment state in which the patient could accomplish the task as specified within 60 seconds.
- To assess the efficacy of intracranial CTX DP in restoring upper limb function following an ischaemic stroke using the ARAT [ Time Frame: 12 months ]
- To assess the efficacy of intracranial CTX DP in restoring function following an ischaemic stroke using the Modified National Institutes of Health Stroke Scale (NIHSS) [ Time Frame: 12 months ]
- To assess the efficacy of intracranial CTX DP in restoring patient's functional independence following an ischaemic stroke using the Rankin Focused Assessment (RFA) version of the modified Rankin Scale [ Time Frame: 12 months ]
- To assess the efficacy of CTX DP in improving patient's ability to execute activities of daily living following an ischaemic stroke using the Barthel Index (BI) [ Time Frame: 12 months ]
- To assess the safety and tolerability of intracranial CTX DP in patients following an ischaemic stroke [ Time Frame: 12 months ]Incidence of adverse events: monitoring of vital signs, temperature, pulse rate and rhythm, ECG, blood pressure, full blood count, liver function test, serum urea and electrolytes, CTX antibody screen
- To assess the efficacy of intracranial CTX DP in restoring upper limb function following an ischaemic stroke using the Fugl-Meyer [ Time Frame: 12 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02117635
|Queen Elizabeth Hospital|
|Birmingham, United Kingdom|
|NHS Southern General Hospital|
|Glasgow, United Kingdom, G51 4TF|
|Kings College Hospital|
|London, United Kingdom|
|University College London Hospital|
|London, United Kingdom|
|Royal Victoria Infirmary|
|Newcastle, United Kingdom|
|Nottingham City Hospital|
|Nottingham, United Kingdom|
|SalfordRoyal NHS Foundation Trust|
|Salford, United Kingdom|
|Royal Hallamshire Hosptial|
|Sheffield, United Kingdom|
|Southampton, United Kingdom|
|Principal Investigator:||Keith W Muir||University of Glasgow|